NEW YORK (GenomeWeb) – Paragon Genomics said today it has closed an $8 million Series A financing round.

According to Paragon CEO Tao Chen, the company plans to use the funds to develop next-generation sequencing assays in the oncology and precision medicine space, and expand its US commercial team. He added that the firm's CleanPlex 2.5-hour multiplex PCR target-enrichment workflow for Illumina NGS platforms has been adopted by more than 50 NGS labs globally, and Paragon is looking to expand into Europe, Asia, and South America through partnership and distributorship deals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.

Sponsored by

This webinar will discuss the advantages of a multiple-biomarker-based approach for immune profiling that provides clinicians with a rational means to consider approved immunotherapies or assign patients to immunotherapy clinical trials.

Sponsored by

This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.

Sponsored by

This webinar will discuss the role of a newly discovered, brain-enriched form of non-CpG DNA methylation in neural development and disease.

Sponsored by
Agilent Technologies

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.